Trials / Unknown
UnknownNCT03175016
Irinotecan-Eluting Bead (DEBIRI) for Patients With Liver Metastases From Colorectal Cancer
Irinotecan-Eluting Bead (DEBIRI) for Unresectable Liver Metastases From Colorectal Cancer After Systemic Chemotherapy Failure
- Status
- Unknown
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 200 (estimated)
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a multicentre, open labeled, single arm study to determine effectiveness and safety of chemoembolization with Irinotecan-Eluting Bead(DEBIRI) in the treatment of unresectable liver metastases in patients with colorectal cancer after chemotherapy failure.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | TACE | Transcatheter arterial chemoembolization（TACE）is a minimally invasive procedure performed to restrict a tumor's blood supply. |
| DRUG | Irinotecan | Irinotecan hydrochloride is a semisynthetic derivative of camptothecin, an alkaloid extracted from the tree Camptotheca acuminata. Irinotecan hydrochloride trihydrate is a pale yellow to yellow crystalline powder, it is mixed in eluting-beads and injected in the tumor. |
| DEVICE | eluting-bead | The eluting-bead,loaded with irinotecan (DEBIRI) to treat patients with hepatic metastases from colorectal cancer. |
Timeline
- Start date
- 2017-06-20
- Primary completion
- 2019-08-01
- Completion
- 2019-12-01
- First posted
- 2017-06-05
- Last updated
- 2017-06-27
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03175016. Inclusion in this directory is not an endorsement.